NEW HAVEN, CT, Veradermics, a late clinical-stage aesthetics and dermatology-focused biopharmaceutical company developing first-in-class therapeutics for common dermatologic conditions, announced the closing of a $75 million Series B financing.
Veradermics, a late clinical-stage aesthetics and dermatology-focused biopharmaceutical company developing first-in-class therapeutics for common dermatologic conditions, announced the closing of a $75 million Series B financing. The financing was led by Suvretta Capital Management and included new investors Longitude Capital, Surveyor Capital (a Citadel company), Osage University Partners, and PhiFund. Existing investors, JW Childs Associates, Connecticut Innovations, and Vlad Coric, MD, also participated in this round. In connection with this financing, Amanda…
Read Full Article at: VC News Daily